ArticleBMJ open ophthalmology2025
Real-world outcomes of selective laser trabeculoplasty and medical treatment in primary open-angle glaucoma and ocular hypertension.
Article in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Challenges and Limitations of Selective Laser Trabeculoplasty in Modern Glaucoma Management: A Narrative Review.Journal of clinical medicine · 2026Review
- Australian and New Zealand Glaucoma Society (ANZGS) Consensus on Interventional Glaucoma.Clinical & experimental ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveReport effectiveness of selective laser trabeculoplasty (SLT) and topical medical therapy for treatment initiation and escalation.
designMulticentre, retrospective cohort study covering an observation period of 10 years.
participantsPatients with ocular hypertension or primary open-angle glaucoma initiating intraocular pressure (IOP)-lowering therapy, or escalating from a single topical agent.
main outcome measuresKaplan-Meier estimate for duration of treatment success, defined by the time between treatment event to treatment failure, defined as meeting one of the following: a <20% reduction in IOP in comparison to baseline at two consecutive clinic visits; IOP >21 mm Hg at 2 consecutive clinic visits; or subsequent intensification of glaucoma treatment (subsequent increase in medical drops, SLT (re-)treatment, incisional glaucoma therapy).
resultsA total of 4564 eyes (mean baseline IOP 21.8 SD 7.0 mm Hg) of 2708 patients were included. The median time to treatment failure (ie, duration for which treatment success can be expected for 50% of patients) was 1.72 years (95% CI 1.63 to 1.79) following initiation of a topical agent and 1.35 (95% CI 1.13 to 1.73) years after initial SLT.Following escalation in those already on a single topical agent, the median treatment failure time was 1.32 years (95% CI 1.23 to 1.44) for 2 topical agents and 1.53 years (95% CI 1.35 to 2.03) for a single topical agent and SLT.
conclusionThis retrospective analysis reports the real-world effect of SLT and topical medical therapy on IOP and treatment success following the most common treatment scenarios: initiation of IOP-lowering treatment and intensification from a single topical drop. Due to the non-randomised nature of this study, it is not possible to draw firm conclusions regarding the comparative effectiveness of drop and SLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.